Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005797 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00005797 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 125 participants.
The verdict
NCT00005797, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treating patients with hematologic cancers.
Interventions
- DRUG Cyclophosphamide
- DRUG busulfan
- DRUG VP-16
- RADIATION Fractionated Total Body Irradiation (FTBI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 1993-03 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005797
The ClinicalTrials.gov registry entry for NCT00005797 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00005797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005797 about?
NCT00005797 is a clinical study titled "Bone Marrow Transplant in Treating Patients With Hematologic Cancers". RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient the...
What is the current status of trial NCT00005797?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 1993-03. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00005797?
The interventions under investigation include: Cyclophosphamide (DRUG), busulfan (DRUG), VP-16 (DRUG), Fractionated Total Body Irradiation (FTBI) (RADIATION).
Who is sponsoring clinical trial NCT00005797?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.